The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis

AIMS: Renin‐angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present. Sodium‐glucose co‐transporter‐2 inhibit...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes Obes Metab
Autori principali: Scholtes, Rosalie A., van Raalte, Daniël H., Correa‐Rotter, Ricardo, Toto, Robert D., Heerspink, Hiddo J. L., Cain, Valerie, Sjöström, C. David, Sartipy, Peter, Stefánsson, Bergur V.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Publishing Ltd 2019
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7078964/
https://ncbi.nlm.nih.gov/pubmed/31742881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13923
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi